NFX1-123 protein expression was determined by western immunoblot as described previously [9 (link)]. Briefly, cervical cancer cell lines were seeded in 6 well or 10cm plates. 24 hours later, they were treated with Ropitoin (5 to 20 μM), R428 (0.5 to 5 μM), Ketoconazole (10 to 40μM), and Perospirone Hydrochloride (10 to 20μM) and pelleted for protein at 72 hours. DMSO treated cells were pelleted as controls. Cell pellets were lysed with lysis buffer (50mM Tris HCl pH 7.5, 150mM NaCl and 0.01% Triton X-100) and cup sonicated in an ice-bath. 20 to 40 μg of protein was loaded on a 4 to 20% gradient gel (BioRad, Hercules, California, USA) and transferred to PVDF membrane using the Trans Blot Turbo System (BioRad, Hercules, California, USA). Membranes were blocked with 2% blocking agent (Cytiva Lifesciences, Marlborough, MA, USA) for one hour at room temperature. Primary antibodies for NFX1-123 1:500 (Novus Biologicals, Centennial, CO, USA) or GAPDH (Abcam,1:50,000) and HRP conjugated secondary antibodies of anti-rabbit (1:5000 dilution) and anti-mouse (1:50,000) were used.